Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss

Executive Summary

Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.

You may also be interested in...



Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

Stock Watch: Should A Biotech’s First Product Be Out-Licensed Or Self-Marketed?

The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?

COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick

The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel